Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator
Open Access
- 1 September 2009
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (9), 4012-4023
- https://doi.org/10.1210/en.2009-0216
Abstract
Increased matrix extracellular phosphoglycoprotein (MEPE) expression occurs in several phosphate and bone-mineral metabolic disorders. To resolve whether MEPE plays a role, we created a murine model overexpressing MEPE protein (MEPE tgn) in bone. MEPE tgn mice displayed a growth and mineralization defect with altered bone-renal vascularization that persisted to adulthood. The growth mineralization defect was due to a decrease in bone remodeling, and MEPE tgn mice were resistant to diet-induced renal calcification. MEPE protein-derived urinary ASARM peptides and reduced urinary Ca X PO4 product mediated the suppressed renal calcification. Osteoblastic cells displayed reduced activity but normal differentiation. Osteoclastic precursors were unable to differentiate in the presence of osteoblasts. In the kidney, NPT2a up-regulation induced an increase in phosphate renal reabsorption, leading to hyperphosphatemia. We conclude MEPE and MEPE-phosphate-regulating gene with homologies to endopeptidases on the X chromosome (MEPE-PHEX) interactions are components to an age-diet-dependent pathway that regulates bone turnover and mineralization and suppresses renal calcification. This novel pathway also modulates bone-renal vascularization and bone turnover.Keywords
This publication has 49 references indexed in Scilit:
- Matrix Extracellular Phosphoglycoprotein Inhibits Phosphate TransportJournal of the American Society of Nephrology, 2008
- Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndromeAmerican Journal of Medical Genetics Part A, 2008
- Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemiaJCI Insight, 2008
- Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYPEndocrinology, 2007
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007
- Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activityNature Medicine, 2007
- Phosphorylated acidic serine–aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activityJournal of Endocrinology, 2007
- Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatinBone, 2006
- Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)Kidney International, 2005
- Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoproteinBiochemical Journal, 2003